An Ophthalmic Safety Study in Patients With Breast Cancer
← catalyst calendarNCT06767462 · readout in 233 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
160estimated
Sites
50
Countries
Argentina, Belgium, Brazil +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-05 | actual | When the study began enrolling |
| Primary completion | 2027-04-09 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-09 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ophthalmic Safety in Patients With Breast Cancer
Primary outcomes
what the primary-completion date above is the date OFVisual Acuity Testing (Snellen units)
measured Ophthalmic review by central reader until 28 days after End of Study visit.
Slit Lamp examination (normal/abnormal)
measured Ophthalmic review by local ophthalmologist until 28 days after End of Study visit.
Optical Coherence Tonometry (μm)
measured Ophthalmic review by central reader until 28 days after End of Study visit.
Fundus Examination (normal/abnormal)
measured Ophthalmic review by central reader until 28 days after End of Study visit.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed